Monthly lab UPPD data from the previous 8 months, specific to each LTACH, were presented to the group, together with comparative data from 92 other LTACHs.
Following the third phase, the impact of the CVP on subsequent lab utilization was determined for all LTACHs; lab UPPD was measured monthly 8 months prior to the initial meeting (beginning J anuary 2015) and 7 months after the meeting (ending April 2016).
The overall mean lab UPPD 8 months prior to intervention was 3.25 (SD = 1.14); the CMI was 1.24 (SD = 0.13).
Patient safety and outcome measures were examined in a series of paired t tests pre- and postintervention to determine whether reduction in lab UPPD had unintended consequences.
All the LTACHs studied had a decrease in lab UPPD over the 15-month period.
Despite lab UPPD significantly decreasing from pretest to posttest, CMI remained unchanged after the intervention, indicating that lab utilization was not correlated with patient acuity.
Based on the average amount and an unadjusted reduction of 0.49 lab UPPD, the 9 LTACHs studied realized a potential savings of approximately $1,000,000 for the 7 months after the intervention.